MedCity News February 9, 2025
At a moment when medication therapy for sickle cell disease (SCD) leaves too many behind and widespread access to curative gene therapies still lies in the distant future, automated red blood cell exchange is experiencing renewed interest. To improve patients’ lives, a broad commitment is needed to expand access to transfusion therapies.
Given the remarkable advances seen with gene therapies for sickle cell disease (SCD), it may seem counterintuitive to suggest the space may be in need of more therapies that have already been established. Indeed, as cutting-edge therapies face a long journey to treat patients at scale, the community recently faced a setback with the withdrawal of one of the few previously approved drugs over safety concerns. Drug-based therapy,...
Today's Sponsors
Today's Sponsor